Is Landerlan a funded company?

Landerlan is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Landerlan rank among its competitors?

Landerlan ranks 3938th amongst 4054 active competitors, of which 28 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was EBOS Group, which secured $124M in Apr, 2025.

Who are the top competitors of Landerlan?

Landerlan's top competitors include AmerisourceBergen, Entero Healthcare and EBOS Group. Among them, EBOS Group secured the most recent funding round in April, 2025.

Landerlan - 2026 Company Profile & Competitors

Company Details

Manufacturer of pharmaceutical products. It produces a variety of medications, focusing on consistent quality and safety through rigorous manufacturing processes adhering to current regulations. The company utilizes advanced authentication systems to protect consumers. A commitment to employing local workforce contributes to its success. Products undergo stringent quality control measures to ensure efficacy and safety.

Website: landerlan.com
Social

Key Metrics

Stage

Unfunded

Ranked

3938^th among 4054 active competitors

Similar Companies

AmerisourceBergen & 4282 more

View Landerlan's full profile

Landerlan has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Landerlan include AmerisourceBergen, Entero Healthcare and EBOS Group. Here is the list of Top 10 competitors of Landerlan, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AmerisourceBergen 1985, Chesterbrook (United States), Public	Drug Corporation	-	nextGENE Capital, Walgreens Boots Alliance ... & 4 others	68/100
2nd	Entero Healthcare 2018, Mumbai (India), Public	Operator of an integrated healthcare products distribution platform	$59.7M	Orbimed, Millennium Medicare & 38 others	66/100
3rd	EBOS Group 1922, Docklands (Australia), Public	Wholesaler & distributor of healthcare, medical, and pharmaceutical products	-	-	59/100
4th	Keimed 2000, Hyderabad (India), Series B	Pharmaceutical distributor of temperature-sensitive medicines	$16.6M	Mitsui, Apollo Hospitals & 4 others	59/100
5th	Cencora 2001, Conshohocken (United States), Public	Provider of clinical trial logistics and other biopharma outsourcing services	-	-	57/100
6th	CHEPLAPHARM 1998, Mesekenhagen (Germany), Late Stage	Pharmaceutical company that specializes in the development, marketing, and distribution of branded pharmaceutical products	$547M	GIC, Atlantic Park & 4 others	56/100
7th	Target Healthcare 2012, East Kilbride (United Kingdom), Series B	Distributor of pharmaceutical products	$26.1M	Santander	51/100
8th	Dizal Pharma 2017, Pudong (China), Series A	Limited information available	$100M	Lilly Asia Ventures, HongShan & 3 others	49/100
9th	AvKARE 2007, Pulaski (United States), Acquired	Distributor of pharmaceuticals and infection control products	-	-	49/100
10th	Neelkanth Drugs 1989, Delhi (India), Unfunded	Distributor of pharmaceutical products	-	-	47/100
3938th	Landerlan Unfunded	Manufacturer of pharmaceutical products	-	-	16/100